FDA outlines action plan for AI in drug development
FDA has an action plan addressing the use of AI in drug development. AI is presented as a cross-cutting issue that touches every one of the related documents referenced in connection with the plan.
The available material does not identify specific policy steps, implementation timelines, technical requirements, or named programs tied to the action plan.
Originally reported by drugdiscoverynews.comRead the source →
Related coverage